

Kwang Kon Koh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2032685/publications.pdf>

Version: 2024-02-01

73
papers

4,112
citations

117571

34
h-index

123376

61
g-index

74
all docs

74
docs citations

74
times ranked

4623
citing authors

#	ARTICLE	IF	CITATIONS
1	Adiponectin and cardiometabolic trait and mortality: where do we go?. Cardiovascular Research, 2022, 118, 2074-2084.	1.8	13
2	Cardiovascular effects of omega-3 fatty acids: Hope or hype?. Atherosclerosis, 2021, 322, 15-23.	0.4	19
3	New Trends in Dyslipidemia Treatment. Circulation Journal, 2021, 85, 759-768.	0.7	16
4	Left Atrial Thrombus and Multiple Infarcts. Cardiometabolic Syndrome Journal, 2021, 1, 114.	1.0	0
5	Metabolic Syndrome Fact Sheet 2021: Executive Report. Cardiometabolic Syndrome Journal, 2021, 1, 125.	1.0	44
6	Which biomarker to use, when to start, and how to improve adherence for reducing atherosclerotic cardiovascular disease risk?. European Heart Journal, 2021, 42, 1808-1808.	1.0	1
7	Lipoprotein(a) and Cardiovascular Diseases—Revisited. Circulation Journal, 2020, 84, 867-874.	0.7	40
8	Importance of Risk Stratification After Myocardial Infarction and the Need for Its Clinical Application. Circulation Journal, 2019, 83, 713-714.	0.7	0
9	Letter by Koh Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)". Circulation, 2019, 139, 416-417.	1.6	0
10	Impact of Longitudinal Changes in Metabolic Syndrome Status over 2 Years on 10-Year Incident Diabetes Mellitus. Diabetes and Metabolism Journal, 2019, 43, 530.	1.8	23
11	Letter by Koh Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in) Tj ETQq1 1 0.7843d 4 rgBT Overlock 10	1.6	0
12	Letter by Koh Regarding Article, "PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS)". Circulation, 2018, 138, 1283-1284.	1.6	0
13	Letter by Koh Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease". Circulation, 2018, 138, 846-847.	1.6	0
14	Letter by Koh Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation, 2018, 138, 1914-1915.	1.6	0
15	Letter by Koh Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	0
16	Letter by Koh Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes:) Tj ETQq0 0 0 rgBT /Overlock 10	1.6	0
17	Letter by Koh Regarding Articles, "Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China)" and "Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population". Circulation, 2017, 135, e818-e819.	1.6	2
18	Letter by Koh Regarding Article, "Dipeptidyl Peptidase-4 Induces Aortic Valve Calcification by Inhibiting Insulin-Like Growth Factor-1 Signaling in Valvular Interstitial Cells". Circulation, 2017, 136, 1668-1669.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Renin-angiotensin system inhibitor and statins combination therapeutics – what have we learnt?. Expert Opinion on Pharmacotherapy, 2015, 16, 949-953.	0.9	16
20	The role of insulin resistance and metabolic risk factors on culprit coronary plaque. International Journal of Cardiology, 2015, 190, 56-62.	0.8	6
21	How to balance cardiorenometabolic benefits and risks of statins. Atherosclerosis, 2014, 235, 644-648.	0.4	26
22	Rosuvastatin treatment improves arterial stiffness with lowering blood pressure in healthy hypercholesterolemic patients. International Journal of Cardiology, 2014, 176, 1284-1287.	0.8	12
23	Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients. International Journal of Cardiology, 2013, 166, 509-515.	0.8	48
24	Repeated Aborted Sudden Cardiac Death with Long QT Syndrome in a Patient with Anomalous Origin of the Right Coronary Artery from the Left Coronary Cusp. Korean Circulation Journal, 2013, 43, 830.	0.7	3
25	Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. Atherosclerosis, 2012, 220, 537-544.	0.4	52
26	Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. International Journal of Cardiology, 2011, 146, 319-325.	0.8	29
27	Differential metabolic effects of distinct statins. Atherosclerosis, 2011, 215, 1-8.	0.4	116
28	Increasing Prevalence of Metabolic Syndrome in Korea. Diabetes Care, 2011, 34, 1323-1328.	4.3	527
29	Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients. Journal of the American College of Cardiology, 2010, 55, 1209-1216.	1.2	193
30	Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. International Journal of Cardiology, 2010, 140, 73-81.	0.8	68
31	Combination therapy for treatment or prevention of atherosclerosis: Focus on the lipid-RAAS interaction. Atherosclerosis, 2010, 209, 307-313.	0.4	54
32	Clinical Significance of Left Ventricular Torsional Parameters during Supine Bicycle Cardiopulmonary Exercise Echocardiography. Journal of Cardiovascular Imaging, 2009, 17, 2.	0.8	0
33	Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. International Journal of Cardiology, 2009, 133, 23-31.	0.8	35
34	Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis, 2009, 204, 483-490.	0.4	107
35	Vascular and metabolic effects of treatment of combined hyperlipidemia: Focus on statins and fibrates. International Journal of Cardiology, 2008, 124, 149-159.	0.8	45
36	Are statins effective for simultaneously treating dyslipidemias and hypertension?. Atherosclerosis, 2008, 196, 1-8.	0.4	33

#	ARTICLE	IF	CITATIONS
37	Does reversal of oxidative stress and inflammation provide vascular protection?. Cardiovascular Research, 2008, 81, 649-659.	1.8	71
38	Simvastatin Improves Flow-Mediated Dilation but Reduces Adiponectin Levels and Insulin Sensitivity in Hypercholesterolemic Patients. Diabetes Care, 2008, 31, 776-782.	4.3	107
39	Efonidipine Simultaneously Improves Blood Pressure, Endothelial Function, and Metabolic Parameters in Nondiabetic Patients With Hypertension. Diabetes Care, 2007, 30, 1605-1607.	4.3	43
40	Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. Atherosclerosis, 2007, 194, 230-237.	0.4	25
41	Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. International Journal of Cardiology, 2006, 108, 96-100.	0.8	96
42	Vascular and metabolic effects of candesartan: insights from therapeutic interventions. Journal of Hypertension, 2006, 24, S31-S38.	0.3	19
43	Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. European Heart Journal, 2006, 28, 1440-1447.	1.0	43
44	Controversies regarding hormone therapy: Insights from inflammation and hemostasis. Cardiovascular Research, 2006, 70, 22-30.	1.8	30
45	Neovascularization From Coronary Artery Leaking to Fungus Ball in the Lung. Circulation, 2006, 114, e551-2.	1.6	2
46	Additive Beneficial Effects of Fenofibrate Combined With Candesartan in the Treatment of Hypertriglyceridemic Hypertensive Patients. Diabetes Care, 2006, 29, 195-201.	4.3	60
47	Efficacy of Thrombosuction using the Export Aspiration Catheter before Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. Korean Circulation Journal, 2005, 35, 172.	0.7	2
48	Vascular and Metabolic Effects of Combined Therapy With Ramipril and Simvastatin in Patients With Type 2 Diabetes. Hypertension, 2005, 45, 1088-1093.	1.3	146
49	Beneficial Effects of Fenofibrate to Improve Endothelial Dysfunction and Raise Adiponectin Levels in Patients With Primary Hypertriglyceridemia. Diabetes Care, 2005, 28, 1419-1424.	4.3	176
50	Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study. European Heart Journal, 2005, 26, 1362-1368.	1.0	32
51	Additive Beneficial Effects of Fenofibrate Combined With Atorvastatin in the Treatment of Combined Hyperlipidemia. Journal of the American College of Cardiology, 2005, 45, 1649-1653.	1.2	192
52	Inflammatory Markers and the Metabolic Syndrome. Journal of the American College of Cardiology, 2005, 46, 1978-1985.	1.2	332
53	Additive Beneficial Effects of Losartan Combined With Simvastatin in the Treatment of Hypercholesterolemic, Hypertensive Patients. Circulation, 2004, 110, 3687-3692.	1.6	275
54	Simvastatin Combined With Ramipril Treatment in Hypercholesterolemic Patients. Hypertension, 2004, 44, 180-185.	1.3	47

#	ARTICLE	IF	CITATIONS
55	Should Progestins Be Blamed for the Failure of Hormone Replacement Therapy to Reduce Cardiovascular Events in Randomized Controlled Trials?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1171-1179.	1.1	44
56	Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. <i>American Journal of Cardiology</i> , 2004, 93, 1432-1435.	0.7	63
57	Vascular effects of diet and statin in hypercholesterolemic patients. <i>International Journal of Cardiology</i> , 2004, 95, 185-191.	0.8	48
58	Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. <i>International Journal of Cardiology</i> , 2004, 97, 239-244.	0.8	36
59	Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. <i>Atherosclerosis</i> , 2004, 174, 379-383.	0.4	69
60	Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study. <i>Atherosclerosis</i> , 2004, 177, 147-153.	0.4	13
61	Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. <i>Atherosclerosis</i> , 2004, 177, 155-160.	0.4	68
62	Comparative effects of diet and simvastatin on markers of thrombogenicity in patients with coronary artery disease. <i>American Journal of Cardiology</i> , 2003, 91, 1231-1234.	0.7	7
63	Vascular effects of step I diet in hypercholesterolemic patients with coronary artery disease. <i>American Journal of Cardiology</i> , 2003, 92, 708-710.	0.7	11
64	Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. <i>Journal of the American College of Cardiology</i> , 2003, 42, 905-910.	1.2	217
65	Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy?. <i>International Journal of Cardiology</i> , 2003, 87, 1-8.	0.8	31
66	Significant Differential Effects of Hormone Therapy or Tibolone on Markers of Cardiovascular Disease in Postmenopausal Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1889-1894.	1.1	47
67	Evaluation of Sympathetic Reinnervation Using 123I-MIBG Scintigraphy in Cardiac Transplants. <i>Sunhwan'gi</i> , 2003, 33, 909.	0.3	0
68	Effects of Simvastatin Alone or Combined With Ramipril on Nitric Oxide Bioactivity and Inflammation Markers in Hypercholesterolemic Patients. <i>Sunhwan'gi</i> , 2003, 33, 1053.	0.3	10
69	Comparative Effects of Diet and Statin on NO Bioactivity and Matrix Metalloproteinases in Hypercholesterolemic Patients With Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, e19-23.	1.1	87
70	Effects of Continuous Combined Hormone Replacement Therapy on Inflammation in Hypertensive and/or Overweight Postmenopausal Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1459-1464.	1.1	32
71	Effects of estrogen on the vascular wall: vasomotor function and inflammation. <i>Cardiovascular Research</i> , 2002, 55, 714-726.	1.8	85
72	Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women. <i>International Journal of Hematology</i> , 2002, 76, 44-46.	0.7	15

#	ARTICLE	IF	CITATIONS
73	Long-term Outcomes of Primary Stenting in Acute Myocardial Infarction. Sunhwan'gi, 2001, 31, 742.	0.3	0